Home » Stocks » ADMS

Adamas Pharmaceuticals, Inc. (ADMS)

Stock Price: $5.09 USD -0.06 (-1.17%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 231.13M
Revenue (ttm) 79.29M
Net Income (ttm) -53.33M
Shares Out 35.17M
EPS (ttm) -1.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $5.09
Previous Close $5.15
Change ($) -0.06
Change (%) -1.17%
Day's Open 5.15
Day's Range 5.08 - 5.32
Day's Volume 226,466
52-Week Range 2.43 - 9.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

2 weeks ago - Business Wire

Adamas (ADMS) delivered earnings and revenue surprises of 25.00% and -1.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

1 month ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted five new employees restricted...

1 month ago - Business Wire

Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

1 month ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

1 month ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report first quarter 2021 financial results on Monday, May 10, after market close. ...

1 month ago - Business Wire

TUCSON, Ariz. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Parkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to de...

1 month ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

1 month ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

2 months ago - Business Wire

Adamas Pharmaceuticals Inc (NASDAQ: ADMS) has announced the publication of pooled analyses of Gocovri (amantadine) from pivotal studies in Parkinson's disease. Data were published in the peer-reviewed j...

2 months ago - Benzinga

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

2 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted two new employees restricted ...

3 months ago - Business Wire

Adamas (ADMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

3 months ago - Zacks Investment Research

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

3 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

3 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

3 months ago - Business Wire

Adamas (ADMS) delivered earnings and revenue surprises of -20.76% and 1.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.89% over the past year to ($0.64), which m...

3 months ago - Benzinga

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

3 months ago - Business Wire

Adamas Pharmaceuticals (NASDAQ:ADMS) announces its next round of earnings this Tuesday, February 23. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.

3 months ago - Benzinga

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

3 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, February 23, ...

4 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

4 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affect...

4 months ago - Business Wire

-- Total revenues expected to be $20.8 million for fourth quarter 2020  and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020  and $71...

4 months ago - GlobeNewsWire

EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people ...

5 months ago - GlobeNewsWire

Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition

5 months ago - GlobeNewsWire

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people ...

5 months ago - GlobeNewsWire

EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted two new empl...

6 months ago - GlobeNewsWire

Amended terms will provide added flexibility to help drive the growth of the Company Amended terms will provide added flexibility to help drive the growth of the Company

6 months ago - GlobeNewsWire

As part of this agreement Adamas will acquire the global rights to OSMOLEX ER® As part of this agreement Adamas will acquire the global rights to OSMOLEX ER®

6 months ago - GlobeNewsWire

EMERYVILLE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people ...

6 months ago - GlobeNewsWire

EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people a...

6 months ago - GlobeNewsWire

EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people ...

6 months ago - GlobeNewsWire

EMERYVILLE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new em...

6 months ago - GlobeNewsWire

Adamas Pharmaceuticals recently reported its Q3 earnings with a slight beat on EPS and a slight miss on revenue. The company did report record product sales for GOCOVRI. Adamas looks to have found a rhy...

6 months ago - Seeking Alpha

Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q3 2020 Results -Earnings Call Transcript

7 months ago - Seeking Alpha

Adamas (ADMS) delivered earnings and revenue surprises of 16.00% and -5.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019

7 months ago - GlobeNewsWire

EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people ...

7 months ago - GlobeNewsWire

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November ...

7 months ago - GlobeNewsWire

EMERYVILLE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people a...

8 months ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to peopl...

9 months ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to peop...

9 months ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to peopl...

9 months ago - GlobeNewsWire

Adamas Pharmaceuticals recently reported their Q2 earnings with a strong beat on EPS and revenue. The market responded appropriately with the stock nearly doubling in subsequent trading days.

10 months ago - Seeking Alpha

Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

About ADMS

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Apr 10, 2014
CEO
Neil McFarlane
Employees
138
Stock Exchange
NASDAQ
Ticker Symbol
ADMS
Full Company Profile

Financial Performance

In 2020, ADMS's revenue was $74.46 million, an increase of 36.28% compared to the previous year's $54.64 million. Losses were -$57.40 million, -45.43% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for ADMS stock is "Buy." The 12-month stock price forecast is 8.79, which is an increase of 72.69% from the latest price.

Price Target
$8.79
(72.69% upside)
Analyst Consensus: Buy